Latest News

Patanjali Foods (NSE:PATANJALI) has had a rough three months with its share price down 8.1%. We, however decided to...

With a price-to-earnings (or "P/E") ratio of 34.9x Maruti Suzuki India Limited ( NSE:MARUTI ) may be sending bearish...

When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 25x, you may consider...

Key Insights Aurobindo Pharma's estimated fair value is ₹968 based on 2 Stage Free Cash Flow to Equity Aurobindo...

There wouldn't be many who think Hindustan Zinc Limited's ( NSE:HINDZINC ) price-to-earnings (or "P/E") ratio of 23.6x...

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Tata Communications fair value estimate is ₹1,823 Current...

Iida Group Holdings Co., Ltd. ( TSE:3291 ) has announced that it will pay a dividend of ¥45.00 per share on the 29th of...

The board of Fujicco Co., Ltd. ( TSE:2908 ) has announced that it will pay a dividend on the 2nd of June, with...

Shanghai Henlius Biotech (SEHK:2696) just cleared a key hurdle by securing US FDA approval of its IND for HLX18, a nivolumab biosimilar, which paves the way for phase 1 trials in multiple solid tumors. See our latest analysis for Shanghai Henlius Biotech. That HLX18 milestone lands after a busy year for Henlius, with HLX22 plus HLX87 also moving deeper into breast cancer trials. It comes despite a 90 day share price return of minus 19.39 percent and a still eye catching three year total...

In recent days, Mastercard disclosed a series of partnerships and product launches, including Loan on Card with LoanPro, expanded wallet capabilities with TerraPay, and enhanced ecommerce acceptance with WooCommerce, alongside a 14% quarterly dividend increase to US$0.87 per share and authorization for up to US$14.00 billion in share repurchases. Together, these moves signal Mastercard’s push to deepen its role in digital lending and wallets while returning more cash to shareholders through...

HORNBACH Holding KGaA (XTRA:HBH) has posted its Q3 2026 numbers with revenue of €1.5 billion and EPS of €0.64, alongside net income of €10.2 million, setting a measured tone for the latest update. The company has seen revenue move from €1.51 billion in Q3 2025 to €1.54 billion in Q3 2026, while trailing 12 month EPS sat at €8.34 and total revenue at €6.39 billion, giving investors a clear read on scale and profitability as net margins continue to edge lower. Overall, the release points to a...

Earlier this month, Mizuho Securities analyst Yaron Kinar downgraded Everest Group to a hold rating, signaling a more cautious stance on the insurer. The downgrade comes from an analyst with a very strong one-year track record, which may carry extra weight in shaping investor expectations. Next, we'll assess how this high-conviction downgrade could influence Everest Group's investment narrative and risk-reward profile. Explore 28 top quantum computing companies leading the revolution in...

CStone Pharmaceuticals announced on 8 December 2025 that its targeted therapy GAVRETO (pralsetinib, 100 mg) has been included in China’s latest National Reimbursement Drug List, which will take effect on 1 January 2026 and broaden reimbursed access for RET-altered lung and thyroid cancer patients. The NRDL inclusion, combined with CStone’s existing commercialization partnership with Shanghai Allist in Mainland China, underscores how alliance-driven distribution is central to expanding...

Deutsche Konsum REIT-AG (XTRA:DKG) has just wrapped up FY 2025 with Q4 total revenue of €38.3 million and a net loss (excluding extra items) of €22.4 million, alongside negative Funds From Operations (FFO) of €9.9 million that will catch income-focused REIT investors’ attention. The company has seen quarterly revenue move from €25.6 million in Q1 2025 to €29.6 million in Q2 and €29.0 million in Q3 before reaching €38.3 million in Q4, while EPS swung from a modest €0.05 in Q1 to losses of €0.8...

Corporación América Airports (NYSE:CAAP) just posted another month of steady traffic growth, with November passenger numbers up about 9% year on year and Argentina leading gains thanks to new routes and added frequencies. See our latest analysis for Corporación América Airports. The market seems to be catching on to that steady operational momentum, with a 30 day share price return of 13.71% and a powerful three year total shareholder return above 200% underscoring how sentiment has shifted...

If you are wondering whether Nasdaq is still attractive after such a strong run, or if the upside has already been priced in, this article will walk you through what the numbers say about its value. Nasdaq's share price has climbed to around $95.36, delivering roughly 1.9% over the last week, 10.9% over the last month, and 23.2% year to date, with 24.2% over 1 year, 62.4% over 3 years, and 138.1% over 5 years. Behind those gains, Nasdaq has stayed in the spotlight as a crucial infrastructure...

If you are wondering whether ZIM Integrated Shipping Services is still a bargain or if the easy money has already been made, this article will walk through what the numbers are really saying about its value. The stock has been anything but quiet lately, with shares up 2.6% over the last week, 14.9% over the past month, and 36.3% over the last year, even though it remains down 17.5% year to date. These moves have been driven in part by shifting expectations around global freight rates and...

If you are wondering whether Patterson-UTI Energy is a bargain or a value trap at today’s price, you are not alone. This breakdown is designed to give you a clear, no-jargon answer. The stock has slipped 6.1% over the last week and is down 31.7% year to date, yet it is still up 25.6% over five years. This highlights how cyclical this name can be. Recent headlines have focused on shifting North American drilling activity and ongoing consolidation in oilfield services, both of which directly...

Wondering if A. O. Smith at around $68 a share is quietly undervalued or just fairly priced? You are not alone, and that is exactly what we are going to unpack here. Despite only a 1.0% return over the last year, the stock has climbed 6.9% in the past month after a softer 1.0% dip over the last week, hinting that sentiment may be shifting again. Recent headlines have focused on A. O. Smith expanding its water treatment and high efficiency water heating offerings, plus ongoing investment in...

Bank Midwest Partnership Puts Raymond James in Focus Raymond James Financial (RJF) just deepened its regional footprint through a new partnership with Bank Midwest, which is moving about $692 million in client assets and rebranding its wealth arm on Raymond James infrastructure. See our latest analysis for Raymond James Financial. That backdrop helps explain why investors have been comfortable paying around $163.01 today, with a modestly positive year to date share price return alongside a...

USA Rare Earth (USAR) has quietly turned heads after a choppy stretch, with the stock bouncing 2% in the latest session even as it remains down over the past 3 months. See our latest analysis for USA Rare Earth. With the share price now at $13.84, the stock’s 1 day share price return of 2.40% offers a small bounce against a still weak 90 day share price return of 14.83%. At the same time, the 1 year total shareholder return of 25.92% hints that longer term momentum is not entirely broken. If...

Bausch Health Companies (NYSE:BHC) just reported strong early participation in its exchange offer, with investors tendering roughly 2.7 billion dollars of existing 2028 secured notes into new 10.0% notes due 2032. See our latest analysis for Bausch Health Companies. This heavy early take up comes as the 1 month share price return of 13.72 percent has started to claw back some of this year’s weakness. The 1 year total shareholder return remains negative, but the 3 year total shareholder return...

Nuvalent (NUVL) just saw a fresh jolt of attention after veteran oncology executive Ron Squarer joined its board, a move that arrived as Wall Street sentiment toward the cancer focused biotech has turned more confident. See our latest analysis for Nuvalent. That backdrop of growing confidence is showing up in the numbers, with Nuvalent’s share price at $103.8 after a strong 90 day share price return of 35.39 percent and an impressive three year total shareholder return of 264.98 percent. This...